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Abstract 
A review is made, analyzing marginal bone loss in relation to the depth of implant insertion with platform switching, 
according to the position of the neck (supracrestal, crestal or subcrestal), and evaluating survival of the implants.
A PubMed search was made of the studies in animals and humans published between 2005 and 2011, specifying 
platform insertion depth (supracrestal, crestal or subcrestal) and registering marginal bone loss from the time of 
prosthetic restoration to the end of follow-up (minimum 6 months). A total of 30 studies were included.
The bone loss associated with implants placed at supracrestal level was slightly smaller than in the case of implants 
placed at subcrestal level, though statistical significance was not reached. The mean marginal bone loss values were 
0.0 mm to 0.9±0.4 mm for the implants with the neck located at supracrestal level; 0.05 mm to 1.40±0.50 mm for 
those at subcrestal level; and 0.26±0.22 mm to 1.8±0.39 mm for those in a crestal location, after 6-60 months of 
follow-up. The survival rate was 88.6-100% for the implants with the neck positioned at crestal level, versus 98.3-
100% below the crest, and 100% above the crest. The heterogeneity of the studies (surgical technique, platform 
surface texture, radiographic measurement techniques, etc.) made it difficult to establish a relationship between 
marginal bone loss and the supracrestal, crestal or subcrestal location of platform switching. 
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Introduction
The aim of dental implantology is to preserve the peri-
implant tissues over the long term. However, marginal 
bone loss has been described in the early stages fo-
llowing prosthetic restoration, in apparent relation to the 
location of the implant-abutment interface. Factors such 
as bacterial infiltration (1,2), micro-movements (2) and 
the transmission of stress at the implant-abutment inter-
face give rise to apical migration of the biological width 
(3) in order to isolate and protect the bone from irrita-
tion. With platform switching, the implant-abutment in-
terface (IAI) is displaced horizontally towards the center 
of the platform and separated from the marginal bone. 
Thus, bacterial infiltration, micro-movements and stress 
occur at a distance from the marginal bone, giving rise 
to lesser apical migration of the biological width (2) and 
therefore to less marginal bone reabsorption. Such bone 
loss is also conditioned by the implant platform insertion 
depth, as specified according to the vertical location of 
the implant-abutment interface (i.e., supracrestal, crestal 
or subcrestal).
Marginal bone loss of implants with platform swit-
ching has been related to the length (2,4), diameter (2) 
and surface of the neck (3,5), and to the inter-implant 
distance (6). Regarding insertion depth, some authors 
recommend placing the platform at crestal level or 1-2 
mm below the crest (3,7), with the argument that this 
results in improved maintenance of the marginal bone 
(8). However, the coexistence of other factors (surgical 
technique, platform surface texture, radiographic mea-
surement techniques, etc.) makes it difficult to establish 
a direct relationship between marginal bone loss and the 
supracrestal, crestal or subcrestal location of platform 
switching. 
The present review analyzes marginal bone loss in rela-
tion to the depth of implant insertion with platform swit-
ching, according to the position of the neck (supracres-
tal, crestal or subcrestal), and evaluates survival of the 
implants.
Inclusion criteria and search strategy
A PubMed review was made, covering the period bet-
ween January 2005 and April 2011, referred to margi-
nal bone loss in implants with platform switching. The 
search included animal and human clinical and/or histo-
logical studies specifying platform insertion depth (su-
pracrestal, crestal or subcrestal) and registering the level 
of bone loss from the time of prosthetic restoration to the 
end of follow-up (minimum 6 and 12 months for the ani-
mal (Table 2) and human studies (Table 1), respectively. 
We excluded those studies using bone augmentation te-
chniques and those involving heavy smokers (over 20 
cigarettes/day), since the baseline clinical conditions 
would be different, and the results therefore would not 
be comparable. A total of 30 studies were included.
The PubMed search was based on the following ke-
ywords: platform switching and dental implants, crestal 
level placement, installation depth, platform switching 
and crestal level, platform switching and bone loss. Arti-
cles from the following journals were included: Interna-
tional Journal of Oral and Maxillofacial Implants, Journal 
of Oral and Maxillofacial Surgery, International Journal 
of Periodontics and Restorative Dentistry, International 
Journal of Prosthodontics, Clinical Oral Restorative, and 
Medicina Oral Patologia Oral y Cirugia Bucal.
A total of 105 articles were identified, of which 75 were 
excluded: 12 finite elements analyses; 10 articles repor-
ting no data on bone loss from prosthetic restoration to 
the end of follow-up; 7 studies involving placement with 
bone grafts; one article with a follow-up of under 6 mon-
ths; one study involving smokers of over 20 cigarettes/
day; and 44 articles that failed to specify the level of 
insertion of the implant platform, or which could not be 
accessed. A total of 30 studies were thus finally included. 
The following data were collected from the most rele-
vant publications: authors and year of publication, type 
of study, the presence of a control group (conventional 
platform), the number of implants, the diameters of the 
platforms and abutments, platform insertion depth, mar-
ginal bone loss, duration of follow-up, and implant sur-
vival rate. The following confounding factors were also 
registered: implant system (manufacturer), treatment of 
the implant neck (smooth/rough), and a surgical techni-
que in one or two steps (submerged or non-submerged)
(Table 1, Table 2).
Results
Marginal bone loss according to platform insertion dep-
th
Peri-implant marginal bone loss is conditioned by the 
position of the implant-abutment interface (IAI) in the 
bone crest, horizontally and vertically (9). 
With platform switching, the IAI is displaced horizon-
tally towards the center of the platform and separated 
from the marginal bone. Thus, bacterial infiltration, mi-
cro-movements and stress occur at a distance from the 
marginal bone, giving rise to lesser apical migration of 
the biological width (2) and therefore to less marginal 
bone reabsorption. Most comparative studies in humans 
(2,4,7,8,10-13) and animals (14) have reported greater 
marginal bone loss with conventional platforms than 
with platform switching, though some authors (15-17) 
have found no significant differences.
The IAI is associated with a peri-implant inflammatory 
infiltrate that is partly responsible for crestal bone reab-
sorption (18). A recent study in dogs (1) has shown the 
magnitude of the peri-implant inflammatory infiltrate to 
depend on the insertion depth of the IAI with respect 
to the alveolar crest (supracrestal, crestal or subcrestal). 
Few studies in the literature have evaluated the influence 
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STUDY Type of study
Control 
group
No. 
implants
Implant 
system
Implant platform 
diameter (mm)
Abutment 
diameter 
(mm)
Implant 
platform 
insertion 
depth (mm)
Implant neck 
surface
Surgical 
technique (1 
or 2 steps)
Follow-
up 
(months)
Initial 
bone loss 
(mm)
Bone loss at end 
of follow-up 
(mm)
Mean 
marginal bone 
loss
Survival 
(%)
Success 
(%)
Calvo 
Guirado et 
al. 2011
Prospective 
clinical No 86 Certain Prevail 4.8 4.1 Crestal
Osseotite 
(rough) NS 60 - 0.76 ±0.18 - 97.1 97.1
Linkevicius 
et al. 2010 Prospective clinical Yes
GT:6
GC:6
GT: Prevail; 
3i Biomet 
GC: Prodigy, 
BioHorizons
GT: 4.1
GC: 3.5 and 4 - Crestal - NS 12 -
GT:1.8±0.39 
(mesial)/1.70±0.35 
(distal) 
GC:1.60±0.46 
(mesial)/1.76±0.45 
(distal)
Nonsignificant 
(p>0.05) 100 100
Fickl et al. 
2010 Prospective clinical YES
GT: 75
GC:14
GT: Osseotite 
Certain; 
Biomet 3i
GC: Osseotite 
Certain 
standard-
diameter
GT: 5.0
GC: 4.0 4.1
GT:subcrestal 
GC:crestal
Osseotite dual 
acid etched. 
Internal 
hexagon
S 12
GT: 
0.30±0.07
GC: 
0.68±0.17 
After 12 months: 
CT: 0.39±0.07
GC: 1.00±0.22
Significant 
(p<0.05) 100 100
Cocchetto et 
al. 2010 Prospective clinical No 15 Certain Prevail 5.8 4.1
1 mm 
subcrestal Osseotite NS 18 - 0.05 to 1.63 - 100 100
Wagenberg 
et al. 2010 Prospective clinical No 94 Nobel Biocare 5.0 4 Crestal
Threaded 
(machined 
surface)
S 132 to 168 -
After 132- 168 
months:
84% of the 
surfaces: ≤0.8 
mm.
- 88.6 -
Veis et al. 
2010 
Prospective 
clinical Yes 
GT: 89 
GC: 193
Full Osseotite 
implants, 
Biomet 3i. 
external 
hexagon
GT:5 GT:4
GC1 and GT1:
1-2 mm 
supracrestal; 
GC2 and 
GT2: crestal; 
GC3 and GT3 
: 1-2 mm 
subcrestal 
Rough S 48 to 60 -
After 2 years: 
GT1: 0.69±0.47
GT2: 1.13±0.42
GT3: 0.39±0.52 
GC1: 0.60±0.67
GC2: 1.23±0.96
GC3: 0.81±0.79
Significant (p< 
.001) 100 100 
Canullo et 
al. 2010 Prospective clinical Yes
GT1:17, 
GT2:13, 
GT3:14 
GC:17
Global, Sweden 
& Martina, 
Padova, Italy
GT₁: 4.3
GT₂: 4.8
GT₃: 5.5 GC:3.8 3.8 Crestal
Rough with 
microthreads S 33 -
After 21 months: 
GT₁: 0.99±0.42
GT₂: 0.82±0.36
GT₃: 0.56±0.31
GC: 1.49±0.54 
After 33 months:
GT₁: 0.99±0.42
GT₂: 0.87±0.43
GT₃: 0.64±0.32
GC: 1.48±0.42
Significant 100 100
Vigolo et al. 
2009
Prospective 
clinical Yes
GT:97 
GC:85 3i/implant innovations 5.0 0.45 Crestal Smooth S 60 -
After 12 months: 
GT: 0.60±0.20 
GC: 0.90±0.30
After 60 months:
GT: 0.60±0.20 
GC: 1.10±0.30
Significant 100 100
Crespi et al. 
2009
Prospective 
clinical Yes
GT: 30
GC: 34
GT: Ankylos 
Plus, Dentsply 
Friadent, 
Mannheim, 
Germany
GC: Seven, 
Sweden & 
Martina
GT:5.5 and 4.5
GC: 5.0 and 3.8
0.25
0.35
1 mm 
subcrestal
GT: Morse 
cone (rough)
GC: smooth 
with 0.8 
mm external 
hexagon
NS 24 -
After 12 months: 
GT: 0.78±0.49
GC: 0.73±0.52
After 24 months:
GT: 0.73±0.52
GC: 0.78±0.49
Nonsignificant 100 100
Trammell et 
al. 2009 Prospective clinical Yes
GT: 13
GC: 12
GT:Osseotite 
Certain NTXP, 
Biomet 3i
GC: Osseotite 
Certain, 
Biomet 3i
GT:4.0;5.0 and 6.0 4.5 Crestal Rough S 24 -
After 24 months:
GT: 0.99±O.53
GC: 1.19±0.58 
Significant 100 100
Prosper et 
al. 2009 
Prospective 
clinical Yes
GT: 180
GC:180
Winsix Ltd, 
London, UK
GT1-3 (body/neck): 
3.3/3.8;3.8/4.5;4.5/5.2.
GC:3.3;3.8;4.5
3.3; 3.8; 4.5
Submerged: 
Crestal/ Non-
submerged: 
smooth neck 
supracrestal
Submerged: 
rough. Non-
submerged: 
smooth 
S/NS 24 -
After 12 months: 
GT: (G1: 0.0
G2: 0.021±0.11
G3: 0.0)
GC: (G1:0.27±0.36
G2:0.01±0.09 
G3:0.10±0.27)
After 24 months: 
GT: (G1: 0.0
G2: 0.05±0.23
G3:0.0)
GC: (G1:0.27±0.46
G2:0.04±0.22 
G3:0.19±0.47)
Significant 
(p<0.001) 100
GT:
100
GC:
98.3
Calvo 
Guirado et 
al. 2008 
Prospective 
clinical No 105
Certain Prevail 
Implants 4 and 5 4.1
0.5 mm 
subcrestal Osseotite NS 3 to 16 0.5
After 16 months:
0.6 - 99.1 -
Cappiello et 
al. 2008
Prospective 
clinical Yes
GT: 75
GC: 56
GT:Osseotite 
Certain Prevail 
3i Implant 
Innovations, 
Palm Beach 
Gardens, FL, 
GC:Osseotite 
Certain. 
GT: 4.8
GC: 4.1 4
Subcrestal 
(depth not 
specified)
GT: Osseotite 
Certain 
Prevail. 
Internal 
hexagon. 
GC: Osseotite 
Certain. 
Internal 
hexagon
NS 12 -
After 12 months:
GT: 0.95±0.32
GC: 1.67±0.37 Significant -
GT: 
98.3
GC: 
100
Hürzeler et 
al. 2007
Prospective 
clinical Yes
GT: 14
GC: 8
3i Implant 
Innovations, 
Palm Beach 
Gardens, FL
GT:5.0
GC:4.1 4.1 Epicrestal -
S 12
GT:
-0.09±
0.65
GC: 
1.73±0.46 
After 12 months: 
GT: 0.12±0.40
GC: 0.29±0.12
Significant 100 100
Initial bone loss: bone loss measured at the time of placement of the prosthesis. Final bone loss: bone loss at the end of follow-up. 
GT: test group (switched platform), GC: control group (conventional platform). 
S: submerged; NS: non-submerged.
G1, G2, G3: expanded platform. G1: expanded platform, submerged, with abutment of same diameter. G2: expanded platform, non-submerged. G3: expanded 
platform, submerged, with abutment of lesser diameter. 
G1, G2, G3: conventional platform. G1: conventional platform, submerged, with abutment of same diameter. G2: conventional platform, non-submerged. G3: 
conventional platform submerged, with abutment of lesser diameter. 
Table 1. Human clinical studies with / without a control group. 
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of the insertion depth of implants with platform swit-
ching with respect to bone loss (3,10,14,18).
Crestal position of the platform
A crestal position is defined when the most coronal por-
tion of the implant platform is positioned at the level of 
the crestal bone inter-proximally (19). 
In different human studies (2,4,11,12) the implant pla-
tforms were inserted at bone crest level. In the studies 
included in the present review, bone loss for the pla-
tforms positioned at crestal level varied from 0.26±0.22 
mm (18) to 1.8±0.39 mm (16), after a follow-up ranging 
from 6 months (14,17,18) to 60 months (10,11,20)(Table 
1, Table 2).
Vela-Nebot et al. (21) recorded a mean bone loss of 0.76 
mm and 0.77 mm mesial and distal, respectively, after 
12 months of follow-up. Accordingly, they recommen-
ded the use of platform switching at crestal level for 
preservation of the marginal bone level. When the IAI 
is located at crestal or subcrestal level, the reabsorption 
of 2 mm of marginal crestal bone is observed as a result 
of establishment of the biological width, which acts as 
a mucosal barrier over the crestal bone (10). According 
to Wagenberg et al. (19), the amount of bone reabsorp-
STUDY
Type of 
study
Con-
trol 
group
No. im-
plants
Implant 
system
Implant 
platform 
diameter 
(mm)
Abutment 
diameter 
(mm)
Implant pla-
tform insertion 
depth (mm)
Implant 
neck 
surface
Surgical 
technique (1 
or 2 steps)
Follow-up 
(months)
Initial 
bone loss 
(placement 
of prosthesis)
(mm)
Bone loss at 
end of follow-
up (mm)
Mean mar-
ginal bone 
loss (mm)
Survival 
(%)
Success 
(%)
Jung et al. 
2008 
Pros-
pective 
clinical
No 62
Experimen-
tal, Institut 
Straumann
4.1 3.3
1 and 2A: 1 mm 
supracrestal, 1 
and 2B: 1 mm 
subcrestal, 1 and 
2C: crestal
SLActive, 
Institut 
Straumann 
1: S / 2: NS 6
1A:-0.06±0.55
1B:-1.50±0.65 
1C:-0.38±0.42
1A: 0.17±0.59
1B: 1.32±0.62 
1C: 0.15±0.33
- 100 100
2A:-0.34±0.29
2B:-0.91±1.11
2C:-0.51±0.69
2A: -0.20±0.32
2B: -1.40±0.50
2C: -0.47±0.46
Cochran 
et al. 2009 
Histolo-
gical
No 60
Bone Level, 
Straumann, 
Basel, Swit-
zerland
4.1 3.3
Crestal, 1 mm. 
subcrestal, 1 mm 
supracrestal
SLActive 30 S 30 NS 6 -
S1: -0.34
S2: -1.29
S3: 0.04
NS1: -0.38
NS2: -1.13
NS3: 0.19
- 100 100
Becker et 
al. 2009
Histo-
morpho-
metric 
Yes 72
Camlog® 
Screw-
Line Implant, 
Promte ® 
plus, Camlog 
Biotech-
nologies 
AG, Basel, 
Switzerland
3.8
GT:3.2
GC:3.8
Supracrestal 
0.4 mm 
Machined 
neck 0.4 
mm
NS 6 -
GT: 0.9±0.4
GC: 1.2±0.6
Nonsigni-
ficant
100 100
GT: test group (switched platform), GC: control group (conventional platform).
G1, G2, G3: expanded platform. G1: expanded platform, submerged, with abutment of same diameter. G2: expanded platform, non-submerged. 
G3: expanded platform, submerged, with abutment of lesser diameter. 
G1, G2, G3: conventional platform. G1: conventional platform, submerged, with abutment of same diameter. G2: conventional platform, non-
submerged. G3: conventional platform submerged, with abutment of lesser diameter. 
S: submerged (two-step technique); NS: non-submerged (single-step technique).
S1: supracrestal; S2: crestal; S3: subcrestal.
1: submerged: (1A: 1 mm. supracrestal; 1B: 1 mm. subcrestal; 1C: crestal). 
2: Non-submerged: (2A: 1 mm. supracrestal; 2B: 1 mm. subcrestal; 2C: crestal).
Table 2. Animal studies with / without a control group. 
tion required to establish the biological width decrea-
ses when the implant platform is placed at crestal level. 
These authors observed a marginal reabsorption of ≤ 0.8 
mm at 84% of the measured surfaces, 11-14 years after 
restoration. In this sense, a study in dogs (14) recorded 
minimum bone loss when the platforms were placed at 
crestal level (0.34 mm) and subjected to loading during 
6 months.
However, in a comparative study involving 24 months 
of follow-up, Veis et al. (10) recorded greater marginal 
bone reabsorption with the crestal position than with 
subcrestal insertion, for both conventional platforms and 
platform switching. The bone loss values for conventio-
nal platforms and platform switching at crestal level 
were 1.23±0.96 and 1.13±0.42 mm, respectively.
Supracrestal position of the platform
According to the studies evaluated in the present review, 
bone loss with platforms placed at supracrestal level va-
ried from 0.0 mm (4) to 0.9±0.4 mm (17), after a follow-
up period of between 6 months (14,17,18) and 60 mon-
ths (10,11,20) (Table 1, Table 2). 
Hürzeler et al. (13) inserted 14 platform switching im-
plants at supracrestal level, without specifying the milli-
e177
J Clin Exp Dent. 2012;4(3):e173-9.                                                   Bone loss according to platform switching depth.
meters of depth. The associated bone loss was 0.22±0.53 
mm after 12 months of prosthetic loading. Veis et al. 
(10) in turn placed 34 platform switching implants at su-
pracrestal level, with a recorded bone loss of 0.69±0.47 
mm after 24 months of follow-up.
In a histological study in dogs, Becker et al. (17) placed 
the platforms 0.4 mm above the bone crest. After one 
month of oral exposure, the distance between the shoul-
der of the implant and the first bone-implant contact po-
int (fBIC) increased slightly and then remained stable 
over the next 5 months. These authors postulated that 
horizontal disadjustment in platform switching could 
help reduce the vertical dimension of the biological 
width. However, according to the authors, this was not 
enough to avoid marginal bone reabsorption, though the 
values were low, with an average of 0.9±0.4 mm after 6 
months of follow-up. Histologically, the authors obser-
ved inflammatory infiltration in the proximity of the im-
plant-abutment interface. Although the implant platform 
was positioned above the bone crest and therefore away 
from the bone, it was not possible to estimate the degree 
to which the inflammatory infiltrate could have influen-
ced marginal bone loss during the early stages. Based on 
these results, platform switching could have a limited 
effect in the prevention of marginal bone reabsorption. 
According to Veis et al. (10), these results were due to 
the supracrestal position of the platform. 
Several authors have suggested an association between 
bone loss and platform insertion depth (1,14), with infla-
mmatory infiltration as a linking factor: one way to sepa-
rate inflammation from the bone is to vertically displace 
the implant-abutment interface with respect to the bone 
crest, i.e., placing the platform at supracrestal level. In 
this sense, Cochran et al. (14) reported that lesser bone 
losses would be obtained with platforms placed at su-
pracrestal level. These authors placed 12 switched pla-
tforms at three possible depths (crestal, 1 mm subcrestal, 
and 1 mm supracrestal), obtaining a gain of 0.04 to 0.19 
mm in marginal bone with the platforms placed 1 mm 
above crestal level. In this same line, Jung et al. (18) 
recorded lesser marginal bone loss with the platforms 
placed at crestal level and 1 mm above crestal level. 
According to Hermann et al. (22), if the implant-abutment 
interface (IAI) is positioned above crestal level, margi-
nal bone loss will be smaller than when positioned below 
crestal level, because the supracrestal position increases 
the distance between the inflammatory infiltrate at the 
IAI and the crestal bone.
Subcrestal position of the platform
Among the studies considered in our review, the bone 
loss recorded with platforms placed at subcrestal level 
ranged from 0.05 mm (23) to 1.40±0.50 mm (18) after a 
follow-up of between 6 months (14,17,18) and 60 mon-
ths (10,11,20) (Table 1, Table 2). 
According to Hermann et al. (22), placing the implant-
abutment interface at subcrestal level can cause vertical 
bone reabsorption to establish the biological width. In 
some studies (1,22), when the IAI was positioned below 
crestal level, the inflammatory infiltrate was found to 
be greater, and the resulting vertical bone reabsorption 
increased. Cochran et al. (14) and Jung et al. (18) also 
recorded greater marginal bone loss with platforms in-
serted 1 mm subcrestal, in both submerged and non-sub-
merged implants (1.29 and 1.13 mm; and 1.32 and 1.40 
mm, respectively); however, these values included 1 
mm corresponding to insertion depth with respect to the 
crest. Therefore, minimum bone loss occurred around 
the subcrestal platform (14).
Other studies contradict the above findings. Degidi et al. 
(9) inserted the implant platform 2 mm subcrestal. Af-
ter one year of prosthetic loading there was no marginal 
bone loss, and the crestal bone was maintained 2 mm 
above the implant platform. According to Veis et al. (10), 
platform switching is only of benefit when positioned 
below crestal level. These authors inserted 89 switched 
platforms at all levels (1-2 mm supracrestal, crestal and 
1-2 mm subcrestal); subcrestal platform switching yiel-
ded the lowest bone reabsorption values, followed by 
supracrestal placement (0.39±0.52 mm and 0.69±0.47 
mm, respectively) after 24 months of prosthetic loading. 
The largest bone loss values corresponded to insertion 
at crestal level (1.13±0.42 mm). According to Veis et al. 
(10), the aforementioned studies (1,18) recorded greater 
bone loss with the subcrestal platforms because of the 
radiographic measurement technique used: the authors 
measured the distance between the bone crest and the 
first bone-implant contact point (fBIC). Veis et al. (10) 
used the implant-abutment interface and fBIC as refe-
rence points.
Lee et al. (24) inserted 308 platform switching implants 
with hydroxyapatite (HA) coated necks and 305 tita-
nium plasma-sprayed (TPS) implants. Some were pla-
ced at crestal level, and others 2 mm subcrestal. The HA 
implants placed at crestal level failed 2.89 times more 
often than those positioned 2 mm below crestal level. 
This appears to show that when the rough surface is ex-
posed to the oral environment, bacterial contamination 
and greater bone loss can be expected. In the case of pla-
tforms positioned at subcrestal level, the mucosal barrier 
increases while bone loss decreases (25).
Confounding factors
The different implant designs and geometries, among 
other factors, can influence bone remodeling after im-
plant placement (18), independently of the level of in-
sertion of the platform.
The texture of the implant neck surface (smooth or rough) 
plays an important role in relation to marginal bone loss 
(24,26). Vais et al. (10) took this into account by using 
platforms all with the same roughness, in order to avoid 
this confounding factor. In the study published by Pros-
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per et al. (4), the neck of all the submerged implants had 
a rough surface, while the non-submerged implants pre-
sented a smooth surface. On evaluating implant survival 
according to texture, Lee et al. (24) found the platform 
insertion depth to be a decisive factor. The failure rate of 
the hydroxyapatite-coated Bicon® implants positioned 
at crestal level and 2 mm subcrestal was 10.29% and 
3.01%, respectively, after a mean follow-up of 3.3 years. 
The authors concluded that bacterial contamination is 
more likely with rough-surfaced implants after the pros-
thetic phase when the platform is positioned at crestal 
level. In this context, Todescan et al. (25) postulated that 
platforms placed at subcrestal level tend to extend the 
mucosal barrier, and the probability of periimplantitis 
after the prosthetic phase is therefore lower in the case 
of implants placed 2 mm below the bone crest than in 
implants positioned at crestal level. 
A number of studies have used a range of commercial 
platform switching systems such as Prevail (Biomet 3i)® 
(16,20,23,27), Osseotite Certain (Biomet 3i)® (8,10), 
Global (Sweden & Martina)® (2,15), Novel Active 
(Nobel Biocare)® (19), or Morse taper-type connections 
such as Ankylos (Dentsply Friadent)® (15). In other stu-
dies, platform reduction was achieved by using a pros-
thetic abutment of lesser diameter than the diameter of 
the implant platform, thereby creating controlled hori-
zontal implant-abutment disadjustment (10). According 
to Cochran et al. (14), the Morse taper-type internal con-
nection results in lesser bone loss than the butt-joint con-
nection, because it avoids bacterial contamination and is 
therefore associated with a lesser inflammatory infiltrate 
at the implant-abutment interface. The drawing of con-
clusions becomes more complicated when we moreover 
also consider the magnitude of horizontal disadjustment. 
The existence of abutments of several diameters means 
that they can be used indistinctly to produce such di-
sadjustment. Becker et al. (28) recorded differences in 
marginal bone loss possibly attributable to the different 
horizontal disadjustment magnitudes created (0.3 mm 
versus 0.5 mm). When disadjustment was 0.3 mm and 
0.5 mm, the mean marginal bone loss was seen to be 
1.2±0.2 mm and 1.3±0.4 mm, respectively, one month 
after surgery.
The surgical technique in one or two steps is also a 
confounding factor to be taken into account. With the 
single-step technique or after second surgery, the im-
plant-abutment interface is established, and bacterial 
contamination and inflammatory infiltration of the inter-
face occurs. The unintended exposure of submerged im-
plants during the healing period can result in early bone 
loss (2,29-30). This does not occur while the implants 
remain submerged. However, Jung et al. (18) found no 
significant differences in terms of bone loss between 
submerged and non-submerged implants.
The initial soft tissue thickness (keratinized gums) can 
intervene in marginal bone reabsorption in implants pla-
ced at supracrestal level. In a pilot study, Linkevicius et 
al. (16) found that horizontal disadjustment in platform 
switching does not prevent bone reabsorption if the mu-
cosal thickness at the time of implant placement is 2 mm 
or less.
Other parameters such as the type of connection (inter-
nal/external)(14), or the inclination of the implant, could 
also influence marginal bone loss. The radiographic mea-
surement techniques differed among the examined stu-
dies. As coronal reference points, most authors used the 
implant-abutment interface, with the first bone-implant 
contact point (fBIC) as the most apical point (10,17). 
The coronal reference point used by Vigolo et al. (11) 
was the most apical point of the smooth neck of the im-
plant, inserted at crestal level. This lack of consensus in 
the measurements gives rise to differences in estimating 
the millimeters of marginal bone loss.
Implant survival rate
The survival rates of the platform switching implants 
ranged from 88.6% (19) to 100% (2,8,12,16,23). In re-
lation to the platform insertion depth, the survival rate 
of the implants placed at crestal level was 88.6% (19) 
to 100% (2,16), versus 98.3% (7) to 100% below cres-
tal level (8, 15, 23), and 100% above crestal level (13). 
Veis et al. (10) found healing of the hard and soft peri-
implant tissues in the platform switching implants to be 
successful, independently of the location of the implant 
neck and the consequent degree of marginal bone reab-
sorption.
Conclusions
Platform switching and platform insertion depth are 
two independent factors in relation to marginal bone 
reabsorption. In turn, synergic effects may be observed 
between them: by increasing the horizontal and vertical 
distance between the implant-abutment interface and the 
marginal bone crest, the inflammatory infiltrate is displa-
ced away from the marginal crestal bone, with a reduc-
tion in bone loss. In the implants positioned at supracres-
tal level, bone loss was slightly less pronounced than in 
the case of those positioned at subcrestal level – though 
statistical significance was not reached. Nevertheless, 
crestal insertion or positioning 1-2 mm subcrestal has 
been recommended. Differences in the results of several 
studies, and the existence of confounding factors, ex-
plains the lack of agreement among authors regarding 
the ideal insertion depth. 
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